Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents

Award Number: UG3DA061620
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents - PROJECT SUMMARY: An alarming increase in the rate of opioid abuse among the general population has resulted in a public health emergency since 2017. The striking rise in opioid use disorder has affected Americans broadly, including steady increases in adolescent deaths due to opioid overdose. However, a number of barriers exist for adolescents to gain access to treatment; and current approaches to pharmacotherapy rely on the off-label use of opioids and other agents used in adults with OUD. Through a successful collaboration with NIDA, USWM developed lofexidine for the mitigation of opioid withdrawal symptoms in adults. The Food and Drug Administration (FDA) approved lofexidine tablets (LUCEMYRA®) for this indication in May 2018. Due to the anticipated utility of lofexidine for the treatment of opioid withdrawal in children, USWM has completed all nonclinical prerequisites necessary to initiate studies in adolescents and engaged with FDA to confirm the approach to registration. The goal of this project is to further NIDA-USWM collaboration to complete FDA development requirements for the approval of Lucemyra in adolescents. The use of an approved medication for opioid withdrawal will provide needed safe and effective treatment options for this underserved patient population to optimize opportunities for initial engagement in treatment and transition to longer term maintenance treatment options, including buprenorphine and extended-release naltrexone, recommended in current guidelines. The proposed research leverages an efficient regulatory pathway using a full extrapolation approach wherein pharmacokinetic (PK) modeling can bridge established adult efficacy to adolescents through lofexidine exposure matching. The approach requires a PK study in adolescents experiencing acute opioid withdrawal to identify Lucemyra doses producing exposures associated with efficacy in adults, and an open label safety study to provide adequate safety data in support of registration requirements. Key components of the program include: i) completion of a Phase 1 PK in adolescents to complete efficacy requirements through exposure matching pediatric extrapolation principles (UG3 Aims 1, 2) and completion of a formal FDA meeting to confirm the remaining scope of the development program (UG3 Key go/no go Milestone), and ii) completion of a Phase 2 open label safety study which, together with the initial Phase 1 study, can be integrated to satisfy the safety package requirements for a supplemental new drug application (UG3 Aim 3, UH3 Aims 1 & 3).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$2,199,448 )
2026	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	1	2/26/2026	NEW	-$2,199,448
														Subtotal = -$2,199,448

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	003	1	7/17/2025	NEW	$0
2025	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	001	1	3/18/2025	NEW	$0
2025	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	002	1	4/2/2025	NEW	$0
2025	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	1	10/9/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $2,916,742 )
2024	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	1	7/2/2024	NEW	$2,916,742
2024	2024	USWM LLC	4441 SPRINGDALE RD	LOUISVILLE	KY	40241	JEFFERSON	USA	Drug Use and Addiction Research Programs	001	1	7/18/2024	NEW	$0
														Subtotal = $2,916,742

Grand Total All Awards = $717,294

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents

Award Number: UG3DA061620

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer